NCT07026123View on ClinicalTrials.gov

A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Nal-IRI (Onivyde®)-based treatment

Nal-IRI (Onivyde®) combined with 5-FU/LV is used for metastatic pancreatic ductal adenocarcinoma patients who have progressed after treatment with gemcitabine. The recommended dose of Nal-IRI (Onivyde®) is 70 mg/m\^2, administered intravenously for 90 minutes, once every 2 weeks. In patients known to be homozygous for the UGT1A1 \* 28 allele, the recommended starting dose of Nal-IRI (Onivyde®) is 50 mg/m\^2, administered intravenously within 90 minutes. Based on tolerance, increase the dose of Nal-IRI (Onivyde®) to 70 mg/m\^2 in subsequent cycles.

DRUG

Other second-line treatment

Other second-line treatment

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
collaborator

Servier (Tianjin) Pharmaceutical Co. LTD.

INDUSTRY

lead

RenJi Hospital

OTHER